Spironolactone (BioDeep_00000002365)

 

Secondary id: BioDeep_00000408798

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(1S,2R,2R,9R,10R,11S,15S)-9-(acetylsulfanyl)-2,15-dimethylspiro[oxolane-2,14-tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan]-6-ene-5,5-dione

化学式: C24H32O4S (416.2021192)
中文名称: 螺内酯
谱图信息: 最多检出来源 Homo sapiens(blood) 1.42%

Reviewed

Last reviewed on 2024-10-11.

Cite this Page

Spironolactone. BioDeep Database v3. PANOMIX ltd, a top metabolomics service provider from China. https://query.biodeep.cn/s/spironolactone (retrieved 2024-11-26) (BioDeep RN: BioDeep_00000002365). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

分子结构信息

SMILES: CC(=O)SC1CC2=CC(=O)CCC2(C)C2CCC3(C)C(CCC34CCC(=O)O4)C12
InChI: InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3

描述信息

Latex as found in nature is a milky fluid found in 10\\\% of all flowering plants (angiosperms). It is a complex emulsion consisting of proteins, alkaloids, starches, sugars, oils, tannins, resins, and gums that coagulates on exposure to air. It is usually exuded after tissue injury. In most plants, latex is white, but some have yellow, orange, or scarlet latex. Since the 17th century, latex has been used as a term for the fluid substance in plants. It serves mainly as defense against herbivorous insects. Many people are allergic to latex. [Wikipedia].
A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D000451 - Mineralocorticoid Receptor Antagonists
C - Cardiovascular system > C03 - Diuretics > C03D - Aldosterone antagonists and other potassium-sparing agents > C03DA - Aldosterone antagonists
C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49186 - Potassium-Sparing Diuretic
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
D045283 - Natriuretic Agents > D004232 - Diuretics
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2902

Spironolactone. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=52-01-7 (retrieved 2024-10-11) (CAS RN: 52-01-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

同义名列表

60 个代谢物同义名

(1S,2R,2R,9R,10R,11S,15S)-9-(acetylsulfanyl)-2,15-dimethylspiro[oxolane-2,14-tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan]-6-ene-5,5-dione; CT Arzneimittel brand OF spironolactone; CT-Arzneimittel brand OF spironolactone; Mayoly-spindler brand OF spironolactone; Pharmafrid brand OF spironolactone; Merck dura brand OF spironolactone; Alphapharm brand OF spironolactone; Jenapharm brand OF spironolactone; Betapharm brand OF spironolactone; Ashbourne brand OF spironolactone; Novopharm brand OF spironolactone; Generosan brand OF spironolactone; Azupharma brand OF spironolactone; Alpharma brand OF spironolactone; Hormosan brand OF spironolactone; Mundogen brand OF spironolactone; Wörwag brand OF spironolactone; Cardel brand OF spironolactone; Pfizer brand OF spironolactone; Searle brand OF spironolactone; Alter brand OF spironolactone; Roche brand OF spironolactone; Dexo brand OF spironolactone; Espironolactona mundogen; Espironolactona alter; Espironolactona; Spironolactonum; Spironolattone; Spironolactone; Novo spiroton; CT, Spiro von; Novo-spiroton; Von CT, spiro; Spiro l.u.t.; NovoSpiroton; Spirolactone; Spirono-isis; MLS000678252; Spiro von CT; Spirono isis; Verospirone; Aldactone a; Veroshpiron; Duraspiron; Spirospare; Verospiron; Aquareduct; Jenaspiron; Spirogamma; Spironone; Aldactone; Spiractin; Spirolang; Spirobeta; Frumikal; Practon; Flumach; Latex; Spironolactone; Spironolactone



数据库引用编号

24 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Juan Hao, Panpan Qiang, Lili Fan, Yunzhao Xiong, Yi Chang, Fan Yang, Xiangting Wang, Tatsuo Shimosawa, Shengyu Mu, Qingyou Xu. Eplerenone reduces lymphangiogenesis in the contralateral kidneys of UUO rats. Scientific reports. 2024 05; 14(1):9976. doi: 10.1038/s41598-024-60636-z. [PMID: 38693148]
  • Chenxiao Xu, Tao Chen, Dan Mo, Tingting Zhang, Fangli Zhou, Haoming Tian, Yan Ren. [Metabolic Outcomes of Primary Aldosteronism Patients Receiving Adrenalectomy or Spironolactone Treatments]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition. 2023 Nov; 54(6):1227-1232. doi: 10.12182/20231160501. [PMID: 38162054]
  • Elisa Schena, Elisabetta Mattioli, Chiara Peres, Laura Zanotti, Paolo Morselli, Patricia Iozzo, Maria Angela Guzzardi, Chiara Bernardini, Monica Forni, Salvatore Nesci, Massimiliano Caprio, Carolina Cecchetti, Uberto Pagotto, Elena Gabusi, Luca Cattini, Gina Lisignoli, William Blalock, Alessandra Gambineri, Giovanna Lattanzi. Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction. Cells. 2023 11; 12(22):. doi: 10.3390/cells12222586. [PMID: 37998321]
  • Song-Li Hao, Chun-Lan Zhang, Xiao-Yu Meng. Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis. Medicine. 2023 Oct; 102(41):e35152. doi: 10.1097/md.0000000000035152. [PMID: 37832133]
  • Junhua Xiao. Sphingosine 1-Phosphate Lyase in the Developing and Injured Nervous System: a Dichotomy?. Molecular neurobiology. 2023 Jul; ?(?):. doi: 10.1007/s12035-023-03524-3. [PMID: 37507574]
  • Kehinde S Olaniyi, Stephanie E Areloegbe, Emmanuel D Areola, Isaiah W Sabinari, Adedamola A Fafure, Richard D Agbana, Chukwubueze L Atuma, Mohd Zahoor Ul Haq Shah, Isaac O Ajadi, Lawrence A Olatunji. Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. Toxicology and applied pharmacology. 2023 Jun; 473(?):116604. doi: 10.1016/j.taap.2023.116604. [PMID: 37328115]
  • Zhe Chen, Xuling Luo, Meiqing Liu, Jinyong Jiang, Yao Li, Zhen Huang, Lingzhi Wang, Jiangang Cao, Lu He, Shifang Huang, Haoliang Hu, Lanfang Li, Linxi Chen. Elabela-apelin-12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1-P2X7 signaling pathway. Journal of cellular biochemistry. 2023 Mar; ?(?):. doi: 10.1002/jcb.30392. [PMID: 36855998]
  • Felix Atmanspacher, Rolf Schreckenberg, Annemarie Wolf, Ivica Grgic, Klaus-Dieter Schlüter. Effect of Metabolic Adaptation by Voluntary Running Wheel Activity and Aldosterone Inhibition on Renal Function in Female Spontaneously Hypertensive Rats. Cells. 2022 12; 11(24):. doi: 10.3390/cells11243954. [PMID: 36552716]
  • Thi Minh Phuong Nikrýnová Nguyen, Branislav Štrauch, Ondřej Petrák, Zuzana Krátká, Robert Holaj, Ivana Kurcová, Věra Marešová, Alena Pilková, Jan Hartinger, Petr Waldauf, Tomáš Zelinka, Jiří Widimský. Adherence and blood pressure control in patients with primary aldosteronism. Blood pressure. 2022 12; 31(1):58-63. doi: 10.1080/08037051.2022.2061416. [PMID: 35438025]
  • Jack L Hulse, Javad Habibi, Aderonke E Igbekele, Bingyue Zhang, Jessie Li, Adam Whaley-Connell, James R Sowers, Guanghong Jia. Mineralocorticoid Receptors Mediate Diet-Induced Lipid Infiltration of Skeletal Muscle and Insulin Resistance. Endocrinology. 2022 10; 163(11):. doi: 10.1210/endocr/bqac145. [PMID: 36039677]
  • Mmenyene U Peter, Stephanie E Areloegbe, Christopher O Akintayo, Adesola A Oniyide, Ayodeji Aturamu, Kehinde S Olaniyi. Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. Canadian journal of physiology and pharmacology. 2022 Sep; 100(9):890-902. doi: 10.1139/cjpp-2022-0176. [PMID: 35771488]
  • Panagiotis I Georgianos, Rajiv Agarwal. Management of hypertension in advanced kidney disease. Current opinion in nephrology and hypertension. 2022 07; 31(4):374-379. doi: 10.1097/mnh.0000000000000812. [PMID: 35727171]
  • Ioannis Petrakis, Eleni Drosataki, Ioanna Stavrakaki, Kleio Dermitzaki, Dimitra Lygerou, Myrto Konidaki, Christos Pleros, Nikolaos Kroustalakis, Sevasti Maragkou, Ariadni Androvitsanea, Ioannis Stylianou, Ioannis Zaganas, Kostas Stylianou. The p.Pro482Ala Variant in the CNNM2 Gene Causes Severe Hypomagnesemia Amenable to Treatment with Spironolactone. International journal of molecular sciences. 2022 Jun; 23(13):. doi: 10.3390/ijms23137284. [PMID: 35806288]
  • Pau Llàcer, Julio Núñez, Marina García, Raúl Ruiz, Genoveva López, Martín Fabregate, Cristina Fernández, François Croset, Beatriz Del Hoyo, Antonio Gomis, Luis Manzano. Comparison of chlorthalidone and spironolactone as additional diuretic therapy in patients with acute heart failure and preserved ejection fraction. European heart journal. Acute cardiovascular care. 2022 Jun; 11(4):350-355. doi: 10.1093/ehjacc/zuac006. [PMID: 35167653]
  • Bora Gulhan, Yağmur Ünsal, Demet Baltu, Nur Berna Çelik Ertaş, Gülşah Özdemir, Eda Utine, H Nursun Ozcan, Ali Duzova, Nazli Gönç. Apparent mineralocorticoid excess: A diagnosis beyond classical causes of severe hypertension in a child. Blood pressure monitoring. 2022 Jun; 27(3):208-211. doi: 10.1097/mbp.0000000000000583. [PMID: 35044984]
  • Rishi J Desai, Scott D Solomon, Muthiah Vaduganathan. Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. Journal of cardiac failure. 2022 06; 28(6):1035-1039. doi: 10.1016/j.cardfail.2022.01.012. [PMID: 35114384]
  • Yong-Li Wang, Lan Bai, Xue-Rui Shi, Hong Zhu, Lin-Juan Du, Yuan Liu, Xiao-Xin Ma, Wen-Zhen Lin, Ting Liu, Jian-Yong Sun, Yan Liu, Xu-Guang Guo, Lu-Jun Zhou, Bo-Yan Chen, Shuai Shao, Xiao-Qian Meng, Yu-Lin Li, Ruo-Gu Li, Sheng-Zhong Duan. Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction. Journal of molecular and cellular cardiology. 2022 06; 167(?):40-51. doi: 10.1016/j.yjmcc.2022.03.003. [PMID: 35314145]
  • Job A J Verdonschot, JoÃo Pedro Ferreira, Anne Pizard, Pierpaolo Pellicori, Hans-Peter Brunner La Rocca, Andrew L Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Olivia J Waring, Michiel H T M Henkens, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, Mark R Hazebroek, John G F Cleland, Faiez Zannad, Stephane R B Heymans. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of cardiac failure. 2022 05; 28(5):778-786. doi: 10.1016/j.cardfail.2021.12.005. [PMID: 34933097]
  • Scott Cohen, Hillel Sternlicht, George L Bakris. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Current diabetes reports. 2022 05; 22(5):213-218. doi: 10.1007/s11892-022-01461-4. [PMID: 35441935]
  • Hongmei Zhang, Bin Zhu, Liyang Chang, Xingxing Ye, Rongrong Tian, Luchen He, Dongrong Yu, Hongyu Chen, Yongjun Wang. Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study. BMC nephrology. 2022 03; 23(1):95. doi: 10.1186/s12882-022-02711-z. [PMID: 35247964]
  • Toru Ishikawa, Satoshi Morimoto, Atsuhiro Ichihara. Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism. Hypertension research : official journal of the Japanese Society of Hypertension. 2022 03; 45(3):496-506. doi: 10.1038/s41440-021-00836-6. [PMID: 34961793]
  • Kanthi Bommareddy, Hassan Hamade, Maria A Lopez-Olivo, Mackenzie Wehner, Traci Tosh, John S Barbieri. Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. JAMA dermatology. 2022 Mar; 158(3):275-282. doi: 10.1001/jamadermatol.2021.5866. [PMID: 35138351]
  • Frederik Husum Mårup, Christian Daugaard Peters, Jeppe Hagstrup Christensen, Henrik Birn. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD. BMJ open. 2022 Feb; 12(2):e057503. doi: 10.1136/bmjopen-2021-057503. [PMID: 35190442]
  • Pieter Martens, João Pedro Ferreira, John Vincent, Paula Abreu, Martijn Busselen, Wilfried Mullens, Wai Hong Wilson Tang, Michael Böhm, Bertram Pitt, Faiez Zannad, Patrick Rossignol. Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial. European heart journal. Acute cardiovascular care. 2022 Feb; 11(2):148-159. doi: 10.1093/ehjacc/zuab111. [PMID: 35021200]
  • Linus Haberbosch, Lukas Maurer, Arvid Sandforth, Charlotte Wernicke, Joachim Spranger, Knut Mai, Reiner Jumpertz von Schwartzenberg. Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients. Endocrine-related cancer. 2022 02; 29(3):121-128. doi: 10.1530/erc-21-0202. [PMID: 35014973]
  • Susana Ravassa, Begoña López, João Pedro Ferreira, Nicolas Girerd, Erwan Bozec, Pierpaolo Pellicori, Beatrice Mariottoni, Franco Cosmi, Mark Hazebroek, Job A J Verdonschot, Joe Cuthbert, Johannes Petutschnigg, María U Moreno, Stephane Heymans, Jan A Staessen, Burkert Pieske, Frank Edelmann, Andrew L Clark, John G F Cleland, Faiez Zannad, Javier Díez, Arantxa González. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. European journal of heart failure. 2022 02; 24(2):321-331. doi: 10.1002/ejhf.2394. [PMID: 34841615]
  • Kristina S Lyngsø, Boye L Jensen, Pernille B L Hansen, Henrik Dimke. Endothelial mineralocorticoid receptor ablation confers protection towards endothelial dysfunction in experimental diabetes in mice. Acta physiologica (Oxford, England). 2022 02; 234(2):e13731. doi: 10.1111/apha.13731. [PMID: 34519423]
  • Sai Sindhu Thangaraj, Helle Charlotte Thiesson, Per Svenningsen, Jane Stubbe, Yaseelan Palarasah, Claus Bistrup, Boye L Jensen, Line Aas Mortensen. Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients. American journal of physiology. Renal physiology. 2022 02; 322(2):F138-F149. doi: 10.1152/ajprenal.00104.2021. [PMID: 34894724]
  • Kimio Watanabe, Takayuki Hamada, Keiki Shimada, Takuya Fujimaru, Yugo Ito, Masahiko Nagahama, Fumika Taki, Masaaki Nakayama. Efficacy of renin-angiotensin-aldosterone system blockades for acute phase hypertensive emergencies in patient complicating severe acute kidney injury. CEN case reports. 2022 02; 11(1):105-109. doi: 10.1007/s13730-021-00639-1. [PMID: 34420196]
  • Satoshi Kidoguchi, Kento Kitada, Kazuki Nakajima, Daisuke Nakano, Hiroyuki Ohsaki, Wararat Kittikulsuth, Hideki Kobara, Tsutomu Masaki, Takashi Yokoo, Kazuo Takahashi, Jens Titze, Akira Nishiyama. Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats. Life sciences. 2022 Jan; 289(?):120192. doi: 10.1016/j.lfs.2021.120192. [PMID: 34871664]
  • Elena Rodríguez-Sánchez, José Alberto Navarro-García, Jennifer Aceves-Ripoll, Laura González-Lafuente, Montserrat Baldan-Martin, Fernando de la Cuesta, Gloria Alvarez-Llamas, María G Barderas, Julián Segura, Luis M Ruilope, Gema Ruiz-Hurtado. Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. European heart journal. Cardiovascular pharmacotherapy. 2022 01; 8(1):68-76. doi: 10.1093/ehjcvp/pvaa086. [PMID: 32663251]
  • V Marzolla, A Feraco, F Limana, P Kolkhof, A Armani, M Caprio. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. Journal of endocrinological investigation. 2022 Jan; 45(1):215-220. doi: 10.1007/s40618-021-01635-z. [PMID: 34272678]
  • Nabil N Al-Hashimi, Amjad H El-Sheikh, Manal I Alruwad, Mohanad M Odeh. Solvent Bar Microextraction Combined with HPLC-DAD for Simultaneous Determination of Diuretics in Human Urine and Plasma Samples. Current pharmaceutical biotechnology. 2022; 23(9):1204-1213. doi: 10.2174/1389201022666210222111943. [PMID: 33618643]
  • Michael Eklund, Olof Hellberg, Hans Furuland, Yang Cao, Kent Wall, Erik Nilsson. Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial. Upsala journal of medical sciences. 2022; 127(?):. doi: 10.48101/ujms.v127.8594. [PMID: 35722182]
  • Sai Sindhu Thangaraj, Christina Stolzenburg Oxlund, Micaella Pereira Da Fonseca, Per Svenningsen, Jane Stubbe, Yaseelan Palarasah, Daniel F J Ketelhuth, Ib Abildgaard Jacobsen, Boye L Jensen. The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension. Journal of hypertension. 2022 01; 40(1):153-162. doi: 10.1097/hjh.0000000000002990. [PMID: 34843183]
  • Fabian Hammer, Salvatore S Buehling, Jaber Masyout, Uwe Malzahn, Tobias Hauser, Tilman Auer, Sören Grebe, Martina Feger, Rashad Tuffaha, Gerald Degenhart, Florian Lang, Andreas Pasch, Ioana Alesutan, Christoph Wanner, Vera Krane, Jakob Voelkl. Protective effects of spironolactone on vascular calcification in chronic kidney disease. Biochemical and biophysical research communications. 2021 12; 582(?):28-34. doi: 10.1016/j.bbrc.2021.10.023. [PMID: 34678593]
  • Lorenzo Villa-Zapata, Briggs S Carhart, John R Horn, Philip D Hansten, Vignesh Subbian, Sheila Gephart, Malinda Tan, Andrew Romero, Daniel C Malone. Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2021 Dec; 78(24):2245-2255. doi: 10.1093/ajhp/zxab215. [PMID: 34013341]
  • Yifang Li, Amlan Chakraborty, Brad R S Broughton, Dorota Ferens, Robert E Widdop, Sharon D Ricardo, Chrishan S Samuel. Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021 Dec; 144(?):112256. doi: 10.1016/j.biopha.2021.112256. [PMID: 34607108]
  • Jaejin An, Fang Niu, John J Sim. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021 12; 41(12):998-1008. doi: 10.1002/phar.2633. [PMID: 34655484]
  • João Pedro Ferreira, Nicolas Girerd, Hans-Peter Brunner-La Rocca, Pierpaolo Pellicori, John G Cleland, Patrick Rossignol, Faiez Zannad. No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. Archives of cardiovascular diseases. 2021 12; 114(12):814-817. doi: 10.1016/j.acvd.2021.10.003. [PMID: 34772647]
  • Nitin Kumar, Yu Zuo, Srilakshmi Yalavarthi, Kristina L Hunker, Jason S Knight, Yogendra Kanthi, Andrea T Obi, Santhi K Ganesh. SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. Viruses. 2021 11; 13(11):. doi: 10.3390/v13112209. [PMID: 34835015]
  • Ya A Orlova, Yu L Begrambekova, A G Plisuk. [Expert opinion. Spironolactone: a new twist on an old story]. Kardiologiia. 2021 Oct; 61(10):99-103. doi: 10.18087/cardio.2021.10.n1734. [PMID: 34763644]
  • Moritz Schnelle, Andreas Leha, Abass Eidizadeh, Katharina Fuhlrott, Tobias D Trippel, Djawid Hashemi, Karl Toischer, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Burkert Pieske, Lutz Binder, Frank Edelmann. Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial. Cells. 2021 10; 10(10):. doi: 10.3390/cells10102796. [PMID: 34685778]
  • Chieh-Kai Chan, Yi-Yao Chang, Yi-Chun Tsai, Zheng-Wei Chen, Chun-Yi Wu, Wei-Chieh Huang, I-Weng Yen, Kuo-Hsin Wu, Vin-Cent Wu, Yen-Hung Lin. Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection. Journal of the Formosan Medical Association = Taiwan yi zhi. 2021 Oct; 120(10):1811-1820. doi: 10.1016/j.jfma.2021.03.032. [PMID: 33906783]
  • Nicola C Edwards, Anna M Price, Samir Mehta, Thomas F Hiemstra, Amreen Kaur, Peter J Greasley, David J Webb, Neeraj Dhaun, Iain M MacIntyre, Tariq Farrah, Vanessa Melville, Anna S Herrey, Gemma Slinn, Rebekah Wale, Natalie Ives, David C Wheeler, Ian Wilkinson, Richard P Steeds, Charles J Ferro, Jonathan N Townend. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial. Clinical journal of the American Society of Nephrology : CJASN. 2021 10; 16(10):1491-1501. doi: 10.2215/cjn.01930221. [PMID: 34462286]
  • Yong Wang, Xiaoguang Lu, Xiaoping Wang, Qi Qiu, Ping Zhu, Lin Ma, Xiao Ma, Joerg Herrmann, Xueying Lin, Wei Wang, Xiaolei Xu. atg7-Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity. Circulation research. 2021 10; 129(8):e166-e182. doi: 10.1161/circresaha.121.319104. [PMID: 34384247]
  • Ruwen Böhm, Paul Westermann, Martin Gleim, Ingolf Cascorbi, Matthias Gruenewald, Thomas Herdegen, Henning Ohnesorge. High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). European journal of pain (London, England). 2021 09; 25(8):1739-1750. doi: 10.1002/ejp.1784. [PMID: 33909330]
  • Job A J Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, Hans-Peter Brunner-La Rocca, Andrew L Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, John G F Cleland, Faiez Zannad, Stephane R B Heymans. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular diabetology. 2021 08; 20(1):163. doi: 10.1186/s12933-021-01357-9. [PMID: 34372849]
  • Weiwei Wang, Quanhe Chen, Feilong Zhang, Xuehai Chen, Zhe Xu, Xudong Sun, Jinguo Li, Lianglong Chen, Jianhua Chen. Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study. Clinical cardiology. 2021 Aug; 44(8):1120-1127. doi: 10.1002/clc.23659. [PMID: 34076288]
  • Reham I Amer, Ghada E Yassin, Reem A Mohamed, Ahmed M Fayez. Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. AAPS PharmSciTech. 2021 Jul; 22(5):204. doi: 10.1208/s12249-021-02003-z. [PMID: 34258696]
  • Supanat Burinkul, Krasean Panyakhamlerd, Ammarin Suwan, Punkavee Tuntiviriyapun, Sorawit Wainipitapong. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. The journal of sexual medicine. 2021 07; 18(7):1299-1307. doi: 10.1016/j.jsxm.2021.05.003. [PMID: 34274044]
  • Amanda R Buckallew, Katie B Tellor, Rachel Watson, William Miller, Gina Mbachu, Cameron Whitlock, Jay R Seltzer, Anastasia L Armbruster. Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. European journal of clinical pharmacology. 2021 Jul; 77(7):955-960. doi: 10.1007/s00228-020-03069-7. [PMID: 33449127]
  • Yu-Mei Lou, Zhe-Lan Zheng, Lin-Yuan Xie, Jiang-Fang Lian, Wen-Jun Shen, Jian-Qing Zhou, Guo-Feng Shao, De-Xing Hu. Effects of Spironolactone on Hypoxia-Inducible Factor-1α in the Patients Receiving Coronary Artery Bypass Grafting. Journal of cardiovascular pharmacology. 2021 07; 78(1):e101-e104. doi: 10.1097/fjc.0000000000001040. [PMID: 34173801]
  • Antoniya Kisheva, Yoto Yotov, Trifon Chervenkov, Atanas Angelov, Yana Bocheva. Galectin-3 in patients with atrial fibrillation and restored sinus rhythm. Folia medica. 2021 Jun; 63(3):329-336. doi: 10.3897/folmed.63.e55313. [PMID: 34196141]
  • João Pedro Ferreira, Zohra Lamiral, John J V McMurray, Karl Swedberg, Dirk J van Veldhuisen, John Vincent, Patrick Rossignol, Stuart J Pocock, Bertram Pitt, Faiez Zannad. Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. Circulation. Heart failure. 2021 06; 14(6):e008075. doi: 10.1161/circheartfailure.120.008075. [PMID: 34129365]
  • Ying Wang, Jian Wang, Rong Yang, Piwen Wang, Rene Porche, Samuel Kim, Kabirullah Lutfy, Limei Liu, Theodore C Friedman, Meisheng Jiang, Yanjun Liu. Decreased 11β-Hydroxysteroid Dehydrogenase Type 2 Expression in the Kidney May Contribute to Nicotine/Smoking-Induced Blood Pressure Elevation in Mice. Hypertension (Dallas, Tex. : 1979). 2021 06; 77(6):1940-1952. doi: 10.1161/hypertensionaha.120.16458. [PMID: 33813843]
  • Mengyue Lin, Mulalibike Heizati, Lin Wang, Muyesaier Nurula, Zhikang Yang, Zhongrong Wang, Reyila Abudoyreyimu, Zihao Wu, Nanfang Li. A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. Blood pressure. 2021 06; 30(3):145-153. doi: 10.1080/08037051.2021.1880881. [PMID: 33682538]
  • Darcy Adin, Clarke Atkins, Gabrielle Wallace, Allison Klein. Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs. Journal of veterinary internal medicine. 2021 May; 35(3):1245-1254. doi: 10.1111/jvim.16097. [PMID: 33713485]
  • Dominique M Bovée, Estrellita Uijl, David Severs, Eloisa Rubio-Beltrán, Richard van Veghel, Antoinette Maassen van den Brink, Jaap A Joles, Robert Zietse, Catherina A Cuevas, A H Jan Danser, Ewout J Hoorn. Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease. American journal of physiology. Renal physiology. 2021 04; 320(4):F654-F668. doi: 10.1152/ajprenal.00603.2020. [PMID: 33586496]
  • João Pedro Ferreira, Job Verdonschot, Ping Wang, Anne Pizard, Timothy Collier, Fozia Z Ahmed, Hans-Peter Brunner-La-Rocca, Andrew L Clark, Franco Cosmi, Joe Cuthbert, Javier Díez, Frank Edelmann, Nicolas Girerd, Arantxa González, Stéphanie Grojean, Mark Hazebroek, Javed Khan, Roberto Latini, Mamas A Mamas, Beatrice Mariottoni, Blerim Mujaj, Pierpaolo Pellicori, Johannes Petutschnigg, Burkert Pieske, Patrick Rossignol, Philippe Rouet, Jan A Staessen, John G F Cleland, Stephane Heymans, Faiez Zannad. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC. Heart failure. 2021 04; 9(4):268-277. doi: 10.1016/j.jchf.2020.11.010. [PMID: 33549556]
  • Iris E Beldhuis, Peder L Myhre, Michael Bristow, Brian Claggett, Kevin Damman, James C Fang, Jerome L Fleg, Sonja McKinlay, Eldrin F Lewis, Eileen O'Meara, Bertram Pitt, Sanjiv J Shah, Orly Vardeny, Adriaan A Voors, Marc A Pfeffer, Scott D Solomon, Akshay S Desai. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology. 2021 03; 77(9):1211-1221. doi: 10.1016/j.jacc.2020.12.057. [PMID: 33663739]
  • Peter A McCullough, Gelareh Rahimi, Kristen M Tecson. Ambulatory Worsening of Renal Function in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2021 03; 77(9):1222-1224. doi: 10.1016/j.jacc.2021.01.007. [PMID: 33663740]
  • Christopher Edwards. New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications?. The Journal of clinical endocrinology and metabolism. 2021 03; 106(3):622-635. doi: 10.1210/clinem/dgaa874. [PMID: 33249452]
  • Takeshi Hasegawa, Hiroki Nishiwaki, Erika Ota, William Mm Levack, Hisashi Noma. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. The Cochrane database of systematic reviews. 2021 02; 2(?):CD013109. doi: 10.1002/14651858.cd013109.pub2. [PMID: 33586138]
  • John G F Cleland, João Pedro Ferreira, Beatrice Mariottoni, Pierpaolo Pellicori, Joe Cuthbert, Job A J Verdonschot, Johannes Petutschnigg, Fozia Z Ahmed, Franco Cosmi, Hans-Peter Brunner La Rocca, Mamas A Mamas, Andrew L Clark, Frank Edelmann, Burkert Pieske, Javed Khan, Ken McDonald, Philippe Rouet, Jan A Staessen, Blerim Mujaj, Arantxa González, Javier Diez, Mark Hazebroek, Stephane Heymans, Roberto Latini, Stéphanie Grojean, Anne Pizard, Nicolas Girerd, Patrick Rossignol, Tim J Collier, Faiez Zannad. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. European heart journal. 2021 02; 42(6):684-696. doi: 10.1093/eurheartj/ehaa758. [PMID: 33215209]
  • Ryo Nakamaru, Koichi Yamamoto, Hiroshi Akasaka, Hiromi Rakugi, Isao Kurihara, Takashi Yoneda, Takamasa Ichijo, Takuyuki Katabami, Mika Tsuiki, Norio Wada, Tetsuya Yamada, Hiroki Kobayashi, Kouichi Tamura, Yoshihiro Ogawa, Junji Kawashima, Nobuya Inagaki, Megumi Fujita, Kenji Oki, Kohei Kamemura, Akiyo Tanabe, Mitsuhide Naruse. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism. Hypertension (Dallas, Tex. : 1979). 2021 02; 77(2):537-545. doi: 10.1161/hypertensionaha.120.16449. [PMID: 33356395]
  • Florian Le Billan, Julie Perrot, Elena Carceller, Simon Travers, Say Viengchareun, Peter Kolkhof, Marc Lombès, Jérôme Fagart. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2021 02; 35(2):e21314. doi: 10.1096/fj.202002043rr. [PMID: 33417258]
  • Ningning Wan, Asadur Rahman, Akira Nishiyama. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. Journal of human hypertension. 2021 02; 35(2):148-156. doi: 10.1038/s41371-020-0377-6. [PMID: 32661269]
  • Kehinde S Olaniyi, Adesola A Oniyide, Oluwaseun A Adeyanju, Lekan S Ojulari, Adams O Omoaghe, Oluranti E Olaiya. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS. Toxicology and applied pharmacology. 2021 01; 411(?):115381. doi: 10.1016/j.taap.2020.115381. [PMID: 33359182]
  • Rajiv Agarwal, Peter Kolkhof, George Bakris, Johann Bauersachs, Hermann Haller, Takashi Wada, Faiez Zannad. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. European heart journal. 2021 01; 42(2):152-161. doi: 10.1093/eurheartj/ehaa736. [PMID: 33099609]
  • Alberto Galizzi, Mara Bagardi, Angelica Stranieri, Anna Maria Zanaboni, Dario Malchiodi, Vitaliano Borromeo, Paola Giuseppina Brambilla, Chiara Locatelli. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease. BMC veterinary research. 2021 Jan; 17(1):15. doi: 10.1186/s12917-020-02716-6. [PMID: 33413406]
  • A Goren, C G Wambier, S Herrera, J McCoy, S Vaño-Galván, F Gioia, B Comeche, R Ron, S Serrano-Villar, P M Ramos, F A Cadegiani, M Kovacevic, A Tosti, J Shapiro, R Sinclair. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021 Jan; 35(1):e13-e15. doi: 10.1111/jdv.16953. [PMID: 32977363]
  • C J Leader, G T Wilkins, R J Walker. The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. PloS one. 2021; 16(11):e0260554. doi: 10.1371/journal.pone.0260554. [PMID: 34843581]
  • Christopher Edwards, Oleksandra Klekot, Larisa Halugan, Yuri Korchev. Follow Your Nose: A Key Clue to Understanding and Treating COVID-19. Frontiers in endocrinology. 2021; 12(?):747744. doi: 10.3389/fendo.2021.747744. [PMID: 34867791]
  • Seher Abdurasool Almedeny, Jabbar Yasir Al-Mayah, Mohanmed S Abdulzahra, Najah R Hadi. THE EFFECT OF SPIRONOLACTONE ON SERUM ELECTROLYTES AND RENAL FUNCTION TESTS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2021; 74(10 pt 1):2460-2462. doi: NULL. [PMID: 34897004]
  • Viren H Makhijani, Preethi Irukulapati, Kalynn Van Voorhies, Brayden Fortino, Joyce Besheer. Central amygdala mineralocorticoid receptors modulate alcohol self-administration. Neuropharmacology. 2020 12; 181(?):108337. doi: 10.1016/j.neuropharm.2020.108337. [PMID: 33007359]
  • Christopher S Wilcox, Bertram Pitt. Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?. Journal of cardiovascular pharmacology. 2020 12; 77(3):323-331. doi: 10.1097/fjc.0000000000000960. [PMID: 33278189]
  • V Yu Mareev, Ya A Orlova, A G Plisyk, E P Pavlikova, S T Matskeplishvili, Z A Akopyan, E M Seredenina, A V Potapenko, M A Agapov, D A Asratyan, L I Dyachuk, L M Samokhodskaya, Е А Mershina, V E Sinitsyn, P V Pakhomov, M M Bulanova, A A Fuks, Yu V Mareev, Yu L Begrambekova, А А Kamalov. [Results of Open-Label non-Randomized Comparative Clinical Trial: 'BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)]. Kardiologiia. 2020 12; 60(11):4-15. doi: 10.18087/cardio.2020.11.n1440. [PMID: 33487145]
  • Yu-Fang Lin, Kang-Yung Peng, Chia-Hui Chang, Ya-Hui Hu, Vin-Cent Wu, Shiu-Dong Chung. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism. Endocrinology and metabolism (Seoul, Korea). 2020 12; 35(4):838-846. doi: 10.3803/enm.2020.797. [PMID: 33261310]
  • Mattana Patiyasikunt, Bussabong Chancheewa, Pravit Asawanonda, Nopadon Noppakun, Chanat Kumtornrut. Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: A randomized, double-blind, placebo-controlled trial. The Journal of dermatology. 2020 Dec; 47(12):1411-1416. doi: 10.1111/1346-8138.15559. [PMID: 32857471]
  • Nanfang Li, Mengyue Lin, Mulalibieke Heizhati, Lin Wang, Qin Luo, Yuanyuan Li, Jina Yili, Jing Hong, Xiaoguang Yao, Qing Zhu. Effect of spironolactone on cardiovascular morbidity and mortality in patients with hypertension and glucose metabolism disorders (ESCAM): a study protocol for a pragmatic randomised controlled trial. BMJ open. 2020 11; 10(11):e038694. doi: 10.1136/bmjopen-2020-038694. [PMID: 33444188]
  • Alex M Secora, Jung-Im Shin, Yao Qiao, G Caleb Alexander, Alex R Chang, Leslie A Inker, Josef Coresh, Morgan E Grams. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure. Mayo Clinic proceedings. 2020 11; 95(11):2408-2419. doi: 10.1016/j.mayocp.2020.03.035. [PMID: 33153631]
  • Edmund Ym Chung, Marinella Ruospo, Patrizia Natale, Davide Bolignano, Sankar D Navaneethan, Suetonia C Palmer, Giovanni Fm Strippoli. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. The Cochrane database of systematic reviews. 2020 10; 10(?):CD007004. doi: 10.1002/14651858.cd007004.pub4. [PMID: 33107592]
  • María Valeria Razori, Pamela L Martín, Paula M Maidagan, Ismael R Barosso, Nadia Ciriaci, Romina B Andermatten, Enrique J Sánchez Pozzi, Cecilia L Basiglio, María Laura Ruiz, Marcelo G Roma. Spironolactone ameliorates lipopolysaccharide-induced cholestasis in rats by improving Mrp2 function: Role of transcriptional and post-transcriptional mechanisms. Life sciences. 2020 Oct; 259(?):118352. doi: 10.1016/j.lfs.2020.118352. [PMID: 32860804]
  • Flavio A Cadegiani, Andy Goren, Carlos G Wambier. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Medical hypotheses. 2020 Oct; 143(?):110112. doi: 10.1016/j.mehy.2020.110112. [PMID: 32721806]
  • Jakob Lykke Lindhardt, Per Mose Nielsen, Esben Søvsø Szocska Hansen, Haiyun Qi, Rasmus Stilling Tougaard, Christian Østergaard Mariager, Lotte Bonde Bertelsen, Won Yong Kim, Christoffer Laustsen. The hemodynamic and metabolic effects of spironolactone treatment in acute kidney injury assessed by hyperpolarized MRI. NMR in biomedicine. 2020 10; 33(10):e4371. doi: 10.1002/nbm.4371. [PMID: 32691467]
  • V Yu Mareev, Ya A Orlova, E P Pavlikova, S T Matskeplishvili, Z A Akopyan, A G Plisyk, E M Seredenina, D A Asratyan, A V Potapenko, P S Malakhov, L M Samokhodskaya, E A Mershina, V E Sinitsyn, M M Bulanova, A A Fuks, Yu V Mareev, Yu L Begrambekova, A A Kamalov. [Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial 'BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)']. Kardiologiia. 2020 Sep; 60(8):4-15. doi: 10.18087/cardio.2020.8.n1307. [PMID: 33155953]
  • Panagiotis I Georgianos, Rajiv Agarwal. Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda. Current hypertension reports. 2020 09; 22(10):84. doi: 10.1007/s11906-020-01081-x. [PMID: 32880742]
  • Andreas P Kalogeropoulos, Jincy Thankachen, Javed Butler, James C Fang. Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. European journal of heart failure. 2020 09; 22(9):1600-1610. doi: 10.1002/ejhf.1917. [PMID: 32469156]
  • Pierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, Hans-Peter Brunner-La Rocca, Fozia Z Ahmed, Job Verdonschot, Tim Collier, Joe J Cuthbert, Johannes Petutschnigg, Blerim Mujaj, Nicolas Girerd, Arantxa González, Andrew L Clark, Franco Cosmi, Jan A Staessen, Stephane Heymans, Roberto Latini, Patrick Rossignol, Faiez Zannad, John G F Cleland. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European journal of heart failure. 2020 09; 22(9):1711-1723. doi: 10.1002/ejhf.1716. [PMID: 31950604]
  • Marina Krasnova, Alexander Kulikov, Sergey Okovityi, Dmitry Ivkin, Andrey Karpov, Elena Kaschina, Alexey Smirnov. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Naunyn-Schmiedeberg's archives of pharmacology. 2020 09; 393(9):1649-1658. doi: 10.1007/s00210-020-01873-7. [PMID: 32377771]
  • Christian Adolf, Leah T Braun, Carmina T Fuss, Stefanie Hahner, Heike Künzel, Laura Handgriff, Lisa Sturm, Daniel A Heinrich, Holger Schneider, Martin Bidlingmaier, Martin Reincke. Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. Endocrine. 2020 09; 69(3):625-633. doi: 10.1007/s12020-020-02348-8. [PMID: 32594379]
  • Cong Chen, Xue-Ying Zhu, Dong Li, Qian Lin, Kun Zhou. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis. Medicine. 2020 Aug; 99(34):e21694. doi: 10.1097/md.0000000000021694. [PMID: 32846786]
  • Xue Wang, Yuhai Zhu, Shuanglin Wang, Zhuoqun Wang, Haonan Sun, Yujie He, Wei Yao. Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993). 2020 Aug; 42(6):531-538. doi: 10.1080/10641963.2020.1723615. [PMID: 32020810]
  • Tun-Pin Hsueh, Tung-Hu Tsai. Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone. BMC complementary medicine and therapies. 2020 Aug; 20(1):253. doi: 10.1186/s12906-020-03042-y. [PMID: 32799863]
  • Skander Mulder, Paul Perco, Christina Oxlund, Uzma F Mehdi, Thomas Hankemeier, Ib A Jacobsen, Robert Toto, Hiddo J L Heerspink, Michelle J Pena. Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. Translational research : the journal of laboratory and clinical medicine. 2020 08; 222(?):17-27. doi: 10.1016/j.trsl.2020.04.010. [PMID: 32438071]
  • Patrick Rossignol, Bryan Williams, Martha R Mayo, Suzette Warren, Susan Arthur, Gail Ackourey, William B White, Rajiv Agarwal. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. European journal of heart failure. 2020 08; 22(8):1462-1471. doi: 10.1002/ejhf.1860. [PMID: 32452085]
  • Waleed Ali, George Bakris. Evolution of Patiromer Use: a Review. Current cardiology reports. 2020 07; 22(9):94. doi: 10.1007/s11886-020-01342-w. [PMID: 32648072]
  • Mariam H Abdel Jalil, Noura Abdullah, Mervat M Alsous, Mohammad Saleh, Khawla Abu-Hammour. A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. British journal of clinical pharmacology. 2020 07; 86(7):1267-1280. doi: 10.1111/bcp.14272. [PMID: 32153059]